Clinical Trials Browser

INDUSTRY × Interventional × Glucose × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07473128 2026-03-16

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Phase 3 Not yet recruiting

120 enrolled

Thoracic

Limited Stage Small Cell Lung Cancer

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

340 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05933577 2025-09-24

V940-001

Phase 3 Active not recruiting

1,089 enrolled

Dermatologic

Melanoma

NCT00597909 2024-12-17

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

Phase 2 Terminated

1 enrolled

Lymphoid

Hepatic Encephalopathy, Lymphoma, Follicular

NCT04799249 2024-08-01

PRESERVE 2

Phase 3 Completed

194 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04863248 2023-04-14

PRESERVE 4

Phase 2 Terminated

10 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00753740 2020-06-12

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Phase 2 Withdrawn

Gynecologic

Neoplasms, Ovarian Neoplasms

Clinical Trials

KEYLYNK-001

Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

KEYNOTE-B49

KEYNOTE-B96

V940-001

Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy

PRESERVE 2

PRESERVE 4

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.